Create doacs_nhse.json

amend measure and rename

openprescribing/measures/definitions/doacs_nhse.json

@@ -0,0 +1,93 @@
+{
+  "name": "Proportion of Direct Acting Oral Anticoagulants (DOACs) not prescribed as generic rivaroxaban or generic apixaban",
+  "title": "Percentage DOACs items not prescribed as generic rivaroxaban or generic apixaban",
+  "description": "Percentage DOACs items not prescribed as generic rivaroxaban or generic apixaban",
+  "numerator_short": "DOAC items not prescribed as generic rivaroxaban or generic apixaban",
+  "denominator_short": "DOACs items",
+  "y_label": "Percentage DOACs not prescribed as generic rivaroxaban or generic apixaban",
+  "why_it_matters": [
+    "In September 2024 the NHS in England released <a href='https://www.england.nhs.uk/long-read/commissioning-recommendations-for-national-procurement-for-doacs/' target='_Blank'>",
+    "updated commissioning regulations for DOACs,</a> which state:</p>",
+    "<p><i>For patients commencing treatment for Atrial Fibrillation (AF): subject to the criteria specified in the relevant NICE technology appraisal guidance, clinicians should use ",
+    "the best value DOAC that is clinically appropriate for the patient. </p>",
+    "<p>Table 1 provides the available DOACs ranked from highest to lowest best value according to the September 2024 and confidential framework prices.",
+    "If the highest ranked best value DOAC (generic apixaban or generic rivaroxaban) is contraindicated or not clinically appropriate for the specific patient then, subject to the criteria ",
+    "specified in the relevant NICE technology appraisal guidance, clinicians should then consider the next highest ranked DOAC (edoxaban) and so on until an appropriate treatment is identified.",
+    "<table>",
+    "<thead>",
+    "  <tr>",
+    "    <th style='width:30%'>Overall rank</th>",
+    "    <th>DOAC</th>",
+    "    <th>Notes</th>",
+    "  </tr>",
+    "</thead>",
+    "<tbody>",
+    "  <tr>",
+    "    ",
+    "    <td><b>1 (Best value)</b></td>",
+    "    <td><b>generic rivaroxaban<br>generic apixaban</td>",
+    "    <td><b>Best value once a day treatment<br>Best value twice a day treatment</b></td>",
+    "  </tr>",
+    "  <tr>",
+    "    <td><b>2</b></td>",
+    "    <td><b>Edoxaban (Lixiana®)</b></td>",
+    "    <td><b></td>",
+    "  </tr>",
+    "  <tr>",
+    "    <td>3</td>",
+    "    <td>Xarelto® (branded rivaroxaban)</td>",
+    "    <td> </td>",
+    "  </tr>",
+    "  <tr>",
+    "    <td>4</td>",
+    "    <td>Dabigatran (Pradaxa®)</td>",
+    "    <td> </td>",
+    "  </tr>",
+    "  <tr>",
+    "    <td>5</td>",
+    "    <td>Eliquis® (branded apixaban)</td>",
+    "    <td> </td>",
+    "  </tr>",
+    "</tbody>",
+    "</table>",
+    "</ul>",
+    "</p></i>",
+    "<p>The <a href='https://www.england.nhs.uk/long-read/national-medicines-optimisation-opportunities-2023-24/#9-identifying-patients-with-atrial-fibrillation-and-using-best-value-direct-acting-oral-anticoagulants' target='_Blank'>",
+    "NHS England National Medicines Optimisation Opportunities for 2023/24</a> identify using best value direct-acting oral anticoagulants as an area for improvement.</p>",
+    "<p><b>Please note:</b> OpenPrescribing.net measures have a consistent way of visualising measures, where 'lower is better' ",
+    "and therefore in this case we show the proportion of DOACs which are NOT prescribed as edoxaban or generic apixaban." 
+  ],
+  "tags": [
+    "cardiovascular",
+    "core",
+    "cost",
+    "opportunities"
+  ],
+  "url": null,
+  "is_percentage": true,
+  "is_cost_based": false,
+  "low_is_good": true,
+  "numerator_type": "bnf_items",
+  "numerator_bnf_codes_filter": [
+    "0208020Y0 # Rivaroxaban",
+    "0208020Z0 # Apixaban",
+    "0208020X0 # Dabigatran etexilate",
+    "0208020AA # Edoxaban",
+    "~0208020Z0AA # Apixaban (generic)",
+    "~0208020Y0AA # Rivaroxaban"
+  ],
+ "denominator_type": "bnf_items",
+  "denominator_bnf_codes_filter": [
+    "0208020Y0 # Rivaroxaban",
+    "0208020AA # Edoxaban",
+    "0208020Z0 # Apixaban",
+    "0208020X0 # Dabigatran etexilate"
+  ],  
+"authored_by": "[email protected]",
+  "checked_by": "",
+  "date_reviewed": "2024-09-16",
+  "next_review": "2026-09-16",
+  "measure_complexity": "low",
+  "measure_type": "bnf_code",
+  "radar_exclude": false
+}